This study looks at loncastuximab tesirine, a medicine being tested for certain types of cancer in immune cells. The aim is to see if it helps people with a specific kind of lymphoma (a blood cancer) called Marginal Zone Lymphoma (MZL), which has returned or hasn't responded to other treatments. The study will examine both the good and bad effects this treatment might have.
- Participants will need to meet specific health criteria and be over 18 years old.
- They should be prepared to provide tissue or bone marrow samples for testing.
- Men and women must agree to avoid pregnancy during and for several months after the study.
People with certain other medical conditions or who have had specific treatments recently might not be eligible. Participants will be monitored for their health and response to the treatment. This study is important for finding new ways to treat MZL, but it requires commitment and carries some risks.
How understandable was the trial content above?
Hard to understand
Easy to understand